Financials data is unavailable for this security.
View more
Year on year Wuhan Keqian Biology Co Ltd had net income fall -3.32% from 409.52m to 395.93m despite a 6.27% increase in revenues from 1.00bn to 1.06bn. An increase in the selling, general and administrative costs as a percentage of sales from 24.30% to 27.98% was a component in the falling net income despite rising revenues.
| Gross margin | 66.77% |
|---|---|
| Net profit margin | 33.11% |
| Operating margin | 38.17% |
| Return on assets | 6.86% |
|---|---|
| Return on equity | 8.35% |
| Return on investment | 8.07% |
More ▼
Cash flow in CNYView more
In 2023, Wuhan Keqian Biology Co Ltd increased its cash reserves by 23.67%, or 106.67m. The company earned 538.03m from its operations for a Cash Flow Margin of 50.56%. In addition the company used 329.00m on investing activities and also paid 102.43m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.07 |
|---|---|
| Tangible book value per share | 7.94 |
More ▼
Balance sheet in CNYView more
| Current ratio | 4.14 |
|---|---|
| Quick ratio | 3.93 |
| Total debt/total equity | 0.0681 |
|---|---|
| Total debt/total capital | 0.0637 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 126.32% while earnings per share excluding extraordinary items fell by -3.32%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.87% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 64.59% |
| EPS growth(5 years) | 0.307 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -36.52 |
More ▼
